---
title: "‘Scientist-as-a-Service’: Seattle startup Pauling.AI aims to shrink drug discovery timelines by months"
description: "Seattle startup Pauling.AI uses AI to automate early drug discovery steps, reducing timelines from months to weeks. Founded by Javier Tordable, the company operates on a \"scientist-as-a-service\" model"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/270222645.md"
published_at: "2025-12-18T23:30:27.000Z"
---

# ‘Scientist-as-a-Service’: Seattle startup Pauling.AI aims to shrink drug discovery timelines by months

> Seattle startup Pauling.AI uses AI to automate early drug discovery steps, reducing timelines from months to weeks. Founded by Javier Tordable, the company operates on a "scientist-as-a-service" model, outsourcing initial research to AI. Pauling.AI aims to increase drug approvals and tackle rare diseases, benefiting humanity beyond economic returns. The startup has secured pre-seed funding and serves academic institutions, joining a growing field of AI-biotech ventures.

A Seattle-area startup called Pauling.AI is harnessing artificial intelligence to automate the early steps that lead to the discovery of new drugs. The technology can complete tasks in a matter of weeks that previously required three to six months, said founder and CEO Javier Tordable.

Using AI to accelerate research timelines could ultimately spark an exponential increase in new treatments, proponents say.

“The dream of a lot of people in the field would be that, at some point, we’ll go from 30 or 40 new drugs approved every year to 300 or 400,” Tordable said, “and cure all sorts of diseases.”

Tordable launched his company in 2024 after a 16-year tenure at Google, most recently as the technical director of the company’s healthcare and life sciences initiatives. While he doesn’t have expertise in biology or chemistry, Tordable said he’s skilled at building tech tools that can perform complex tasks — such as those required to create new pharmaceuticals.

The startup operates on a “scientist-as-a-service” model, allowing researchers to outsource early steps in the drug discovery process to AI. The platform performs computational chemistry work, engineering drug candidates and modeling how they might interact with molecules and inhibitors within a cell.

The result is a curated list of small-molecule compounds that scientists can then move into a physical laboratory for testing as therapeutics. In the future, the startup would like to produce more complex compounds as drug candidates, such as antibodies.

To accomplish all of this, Pauling is building automation tools that engage with existing large language models and databases from numerous sources.

The startup has six employees who work remotely. Its leadership includes Chief Scientific Officer Oleksandr Savytskyi, a computational biologist who worked in academia in Ukraine and did research at the Mayo Clinic.

Pauling has secured an undisclosed amount of pre-seed funding from Flex Capital and angel investors. It currently serves less than a dozen customers, including several high-profile academic institutions, Tordable said.

The company joins a burgeoning field of AI-biotech ventures, with numerous Pacific Northwest startups: Variational AI in Vancouver, B.C.; Seattle-based Potato and Synthesize Bio; and Xaira Therapeutics, which is based in San Francisco and has labs in Seattle. Additionally, FutureHouse is a California nonprofit in this sphere.

Ultimately, Tordable hopes that by shrinking the time and cost of drug development, it will become economically feasible to tackle rare diseases that are typically not served by big pharma, providing overlooked patients with treatments and cures.

“The nice thing of working in this field is that we’re not necessarily doing it just for economic returns,” Tordable said. “There’s also an enormous benefit to humanity.”

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Fractional AI 宣佈收購 Fabius | Fractional AI 已收購 Fabius，這是一家利用人工智能自動化銷售和運營工作流程的 Y-Combinator 初創公司。這項收購增強了 Fractional 作為領先的人工智能原生服務提供商的增長，響應了企業對生產性人工智能系 | [Link](https://longbridge.com/en/news/277076974.md) |
| AI 衝擊引發恐慌？紅杉林君叡：軟件公司能夠挺過來 | 紅杉資本的林君叡表示，軟件公司能夠應對人工智能帶來的衝擊，並相信 AI 將改善大多數公司。他提到，AI 的影響是真實的，能夠提升工作效率。儘管市場對 AI 的擔憂影響了軟件股，但紅杉仍專注於利用 AI 增強人類工作成果，並投資於 Rowsp | [Link](https://longbridge.com/en/news/276940068.md) |
| 霍華德·馬克斯表示，人工智能無法與優秀投資者的優勢相媲美 | 霍華德·馬克斯表示，人工智能無法匹敵優秀投資者的優勢 | [Link](https://longbridge.com/en/news/277144576.md) |
| 挪威的財富基金正在利用人工智能來篩查 ESG 風險 | 挪威的財富基金正在利用人工智能篩查 ESG 風險 | [Link](https://longbridge.com/en/news/277085201.md) |
| 忘掉 AI 訓練：AI 推理才是 2026 年真正的盈利來源。以下是值得擁有的兩隻股票 | 推理是人工智能領域的一個顛覆性轉變 | [Link](https://longbridge.com/en/news/276776781.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.